Sumitomo Pharma Co., Ltd.
4506.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥289,624,410 | ¥161,300,552 | ¥321,806,520 | ¥479,929,944 |
| - Cash | ¥23,116,000 | ¥29,047,000 | ¥143,478,000 | ¥202,984,000 |
| + Debt | ¥305,422,000 | ¥418,884,000 | ¥346,372,000 | ¥284,544,000 |
| Enterprise Value | ¥571,930,410 | ¥551,137,552 | ¥524,700,520 | ¥561,489,944 |
| Revenue | ¥398,832,000 | ¥314,558,000 | ¥555,544,000 | ¥560,035,000 |
| % Growth | 26.8% | -43.4% | -0.8% | – |
| Gross Profit | ¥245,395,000 | ¥187,981,000 | ¥376,625,000 | ¥402,908,000 |
| % Margin | 61.5% | 59.8% | 67.8% | 71.9% |
| EBITDA | ¥56,673,000 | -¥281,072,000 | -¥3,498,000 | ¥124,359,000 |
| % Margin | 14.2% | -89.4% | -0.6% | 22.2% |
| Net Income | ¥23,634,000 | -¥314,969,000 | -¥74,512,000 | ¥56,413,000 |
| % Margin | 5.9% | -100.1% | -13.4% | 10.1% |
| EPS Diluted | 59.49 | -792.79 | -187.55 | 141.99 |
| % Growth | 107.5% | -322.7% | -232.1% | – |
| Operating Cash Flow | ¥16,500,000 | -¥241,893,000 | ¥11,937,000 | ¥31,239,000 |
| Capital Expenditures | -¥13,030,000 | -¥15,730,000 | -¥12,742,000 | -¥13,494,000 |
| Free Cash Flow | ¥3,470,000 | -¥257,623,000 | -¥805,000 | ¥17,745,000 |